A Multi-enzyme Protocol Improves Total Proteome Coverage in Extracellular Matrix.

Extracellular matrix (ECM) from decellularized mammalian tissues has been used in many therapeutic applications. The tissue-specific composition of the ECM is critically associated with therapeutic performance. However, ECM translation needs to be improved because of the complex composition and limited understanding of ECM repairing mechanisms due partly to incomplete proteomic interrogation of ECM samples.

Bottom-Up Proteomics Workflow for Studying Multi-organism Systems.

In recent years, discovery proteomics has emerged as a pivotal tool in biological research, especially when studying the intricate relationships among multiple organisms. To delve deeper into these interactions, we pioneered a bottom-up proteomics workflow. Using nanoLC-MS/MS and a label-free quantification method, this work specifically examines the differential protein expression in fleas (Ctenocephalides felis felis) that have been experimentally infected with Bartonella henselae, the causative agent of cat scratch disease (CSD).

Heterogeneous depressive symptom trajectories among women with type 2 diabetes: findings from the Women's Interagency HIV Study.

Background: Depression affects 33% of women with type 2 diabetes (T2D) and leads to increased risks of premature mortality. Fluctuation and variation of depressive presentations can hinder clinical identification.

Purpose: We aimed to identify and examine subgroups characterized by distinct depressive symptom trajectories among women with T2D.

High-affinity T cell receptor ImmTAC® bispecific efficiently redirects T cells to kill tumor cells expressing the cancer-testis antigen PRAME.

Background: PRAME (eferentially expressed ntigen in lanoma) is a cancer-testis antigen expressed in several tumor indications, representing an attractive anticancer target. However, its intracellular location limits targeting by traditional methods. PRAME peptides are presented on the surface of tumor cells by human leukocyte antigen (HLA) molecules, indicating that a T cell receptor (TCR)-based strategy that redirects T cells to kill PRAME tumors could be a novel immunotherapeutic option.